- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer | 3 | GlobeNewswire (USA) | ||
| 09.12. | Oncotelic Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| ONCOTELIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.12. | Oncotelic Therapeutics, Inc.: Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine | 2 | GlobeNewswire (USA) | ||
| 03.12. | Oncotelic Therapeutics, Inc.: Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing | 3 | GlobeNewswire (USA) | ||
| 02.12. | Oncotelic Therapeutics, Inc.: Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs | 124 | GlobeNewswire (Europe) | AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data... ► Artikel lesen | |
| 25.11. | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation | 2 | GlobeNewswire (USA) | ||
| 21.11. | Oncotelic Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 21.11. | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation | 2 | GlobeNewswire (USA) | ||
| 20.11. | Oncotelic Therapeutics, Inc.: Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture | 343 | GlobeNewswire (Europe) | SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTLC) today announces that its joint venture partner, GMP Bio, has completed an independent third-party valuation... ► Artikel lesen | |
| 17.11. | Oncotelic Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.11. | Oncotelic Therapeutics, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 30.10. | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies | 2 | GlobeNewswire (USA) | ||
| 28.10. | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies | 2 | GlobeNewswire (USA) | ||
| 22.10. | Oncotelic Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.09. | Oncotelic Therapeutics, Inc.: Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients | 2 | GlobeNewswire (USA) | ||
| 18.09. | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments | 3 | GlobeNewswire (USA) | ||
| 16.09. | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments | 3 | GlobeNewswire (USA) | ||
| 12.09. | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline | 388 | GlobeNewswire (Europe) | AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage biopharmaceutical company developing transformative... ► Artikel lesen | |
| 04.09. | Oncotelic Therapeutics, Inc.: Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics' Commitment to Innovation, Life-Saving Therapies | 2 | GlobeNewswire (USA) | ||
| 28.08. | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Showcases Robust Pipeline and Founder's Broad Intellectual Property Contributions to Biopharma Industry | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,15 | +0,44 % | Erfreuliche Studiendaten verleihen der BioNTech-Aktie wieder Rückenwind, doch für einen Durchbruch reicht es noch nicht | Vor fünf Jahren dominierte die Aktie von BioNTech noch das Börsengeschehen, mittlerweile schafft das Papier es aber nur noch selten auf das Radar der Anleger. Das Geschäft mit Corona-Impfstoffen ist... ► Artikel lesen | |
| EVOTEC | 5,153 | -0,71 % | Rheinmetall Aktie: Sehr spannend! - BioNTech, Evotec, Klöckner, PNE und Stabilus im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BB BIOTECH | 48,800 | +0,10 % | Jade Biosciences secures $45 million in private placement from BB Biotech | ||
| MEDIGENE | 0,023 | -22,15 % | MEDIGENE AG stürzt ab - ich traue meinen Augen nicht! | ||
| QIAGEN | 38,465 | +0,34 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,156 | -2,85 % | Morgen-Update: Curevac sorgt für Spannung - kommt bald die Entscheidung? | ||
| MODERNA | 25,225 | -0,98 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| VALNEVA | 3,678 | -0,97 % | Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ | IXCHIQ- was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups... ► Artikel lesen | |
| AMGEN | 277,00 | +0,05 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| EPIGENOMICS | 0,890 | -1,11 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 5,662 | +1,04 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 147,85 | -1,10 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| BIOFRONTERA | 2,560 | -4,12 % | BIOFRONTERA AG: Jetzt kippt das Gleichgewicht! | ||
| HEIDELBERG PHARMA | 2,700 | -0,37 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma gibt Veränderungen im Vorstand bekannt - Dr. Dongzhou Jeffery Liu wird Mitglied des Vorstands und Vorstandsvorsitzender | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Personalie
Heidelberg Pharma gibt Veränderungen im Vorstand bekannt - Dr. Dongzhou Jeffery Liu wird Mitglied des Vorstands und... ► Artikel lesen | |
| ILLUMINA | 113,60 | -1,03 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen |
ONCOTELIC THERAPEUTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOTELIC THERAPEUTICS INC finden Sie auf Wallstreet Online.